US employers curb GLP-1 coverage as costs soar during open enrollment

US employers are increasingly restricting reimbursement for GLP-1 weight-loss drugs to control healthcare costs during fall open enrollment. This marks a shift from earlier broad coverage, reflecting cost pressures. The move could affect drugmaker revenues and employee access, but the scale of restrictions remains uncertain.